Celcuity Inc. (CELC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Celcuity Inc. (CELC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
CELC - Celcuity Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$153.22
DETAILS
HIGH:
$171.00
LOW:
$110.00
MEDIAN:
$157.00
CONSENSUS:
$153.22
UPSIDE:
40.70%
Stock News
Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032
MINNEAPOLIS, June 03, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) ("Celcuity" or the "Company"), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications, today announced the pricing of its upsized underwritten public offering of $500,000,000 aggregate principal amount of its 0.
Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032
MINNEAPOLIS, June 03, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) (“Celcuity” or the “Company”), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications, today announced the pricing of its upsized underwritten public offering of $500,000,000 aggregate principal amount of its 0.250% convertible senior notes due 2032 (the “Convertible Notes”). The aggregate principal amount of the offering was increased from the previously announced offering size of $400,000,000.
Celcuity: Selloff On Yesterday's Data Unwarranted - Buy Rating Upheld
Celcuity (CELC) shares dropped over 25% despite Phase 3 VIKTORIA-1 data confirming gedatolisib's best-in-class efficacy in advanced breast cancer. Gedatolisib demonstrated superior progression-free survival and objective response rates versus current standards, supporting blockbuster potential in a $6bn market. FDA approval for HR+/HER2- PIK3CA wild-type breast cancer is expected by July 2026, with a supplementary NDA for the mutant cohort planned.
Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032
MINNEAPOLIS, June 03, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) ("Celcuity" or the "Company"), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications, today announced a proposed underwritten public offering of $400,000,000 aggregate principal amount of its convertible senior notes due 2032 (the "Convertible Notes").
Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032
MINNEAPOLIS, June 03, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) (“Celcuity” or the “Company”), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications, today announced a proposed underwritten public offering of $400,000,000 aggregate principal amount of its convertible senior notes due 2032 (the “Convertible Notes”).
Celcuity Inc. (CELC) Discusses VIKTORIA-1 Trial Results for PIK3CA Mutant Advanced Breast Cancer and Gedatolisib Efficacy Transcript
Celcuity Inc. (CELC) Discusses VIKTORIA-1 Trial Results for PIK3CA Mutant Advanced Breast Cancer and Gedatolisib Efficacy Transcript
What's Going On With Celcuity Stock On Tuesday?
Celcuity Inc. (NASDAQ:CELC) on Tuesday reported detailed efficacy and safety findings from the PIK3CA-mutated cohort of its Phase 3 VIKTORIA-1 trial.
Celcuity plunges after experimental breast cancer treatment data disappoints
Celcuity shares slumped 25% , set for their biggest one-day decline, on Tuesday after its experimental breast cancer treatment extended the period of time a patient lives without the disease worsening but underperformed a previous trial.
Celcuity's Gedatolisib Combination Regimens Doubled the Likelihood of Survival without Disease Progression or Death Compared to Alpelisib plus Fulvestrant in the PIK3CA Mutant Cohort of the Pivotal Phase 3 VIKTORIA-1 Trial in Patients with HR+/HER2- Advanced Breast Cancer
MINNEAPOLIS, June 02, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications, today announced detailed efficacy and safety results from the PIK3CA mutant (“MT”) cohort of the Phase 3 VIKTORIA-1 clinical trial of gedatolisib, an investigational pan-PI3K/mTORC1/2 inhibitor, in adults with hormone receptor positive (“HR+”), human epidermal growth factor receptor 2 negative (“HER2-“), PIK3CA mutated, locally advanced or metastatic breast cancer (“ABC”), following progression on, or after, treatment with a CDK4/6 inhibitor and an aromatase inhibitor. VIKTORIA-1 is the first Phase 3 clinical trial to compare the efficacy of two PI3K/AKT/mTOR (“PAM”) inhibitors in this patient population.
Celcuity to Hold Conference Call to Discuss Results for the PIK3CA Mutant Cohort of the Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib Regimens in HR+/HER- Advanced Breast Cancer on June 2, 2026
MINNEAPOLIS, June 01, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications, today announced it will host a conference call and live webcast to review results from the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial on Tuesday, June 2, 2026 at 8:00 a.m. EDT / 7:00 a.m.
Celcuity To Participate in Upcoming Investor Conferences
MINNEAPOLIS, May 28, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications, today announced that Brian Sullivan, Chief Executive Officer and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences:
Celcuity's Cancer Drug Expansion Could Ignite Massive New Market Opportunity: Analyst
On Thursday, Celcuity Inc. (NASDAQ:CELC) announced amendments to its Phase 3 VIKTORIA-2 clinical trial evaluating gedatolisib as a first-line treatment for patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.
Celcuity Inc. (CELC) Q1 2026 Earnings Call Transcript
Celcuity Inc. (CELC) Q1 2026 Earnings Call Transcript
Celcuity Q1 Earnings Call Highlights
Celcuity NASDAQ: CELC reported a wider first-quarter loss as the biotechnology company increased spending tied to commercial launch preparations and continued development of gedatolisib, its investigational therapy for hormone receptor-positive, HER2-negative advanced breast cancer.
Celcuity Inc. Reports Release of First Quarter 2026 Financial Results and Provides Corporate Update
MINNEAPOLIS, May 14, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications, today announced financial results for the first quarter ended March 31, 2026 and other recent business developments.
Celcuity's Phase 3 VIKTORIA-2 Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer Expanding to Include Endocrine-Sensitive Patients
Development of a gedatolisib formulation for subcutaneous injection is underway; first patent application submitted to the U.S. Patent and Trademark Office Development of a gedatolisib formulation for subcutaneous injection is underway; first patent application submitted to the U.S. Patent and Trademark Office
Celcuity Schedules Release of First Quarter 2026 Financial Results and Webcast/Conference Call
MINNEAPOLIS, May 07, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the first quarter 2026 after the market closes on Thursday, May 14, 2026. Management will host a webcast/teleconference the same day at 4:30 p.m.
Why Is Celcuity Stock Rallying Today?
Celcuity Inc. (NASDAQ:CELC) shares are up during Monday's premarket session following positive news about its Phase 3 VIKTORIA-1 trial results.
Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort
Detailed data for the gedatolisib triplet and doublet regimens will be presented at a late-breaking abstract oral session at the 2026 ASCO Annual Meeting Detailed data for the gedatolisib triplet and doublet regimens will be presented at a late-breaking abstract oral session at the 2026 ASCO Annual Meeting
Price Targets
Celcuity price target lowered to $171 from $189 at Craig-Hallum
$171.00
(was $89.12)
Craig-Hallum
Celcuity price target lowered to $145 from $185 at H.C. Wainwright
$145.00
(was $91.42)
H.C. Wainwright
Celcuity Inc (CELC) PT Lowered to $166 at Wells Fargo
$166.00
(was $91.42)
Eva Fortea Verdejo
·
Wells Fargo
Celcuity Inc (CELC) PT Lowered to $155 at Leerink, 'we expect CELC shares to be under pressure given the lofty expectations'
$155.00
(was $93.37)
Andrew Berens
·
Leerink Partners
Celcuity (CELC) Reiterated at Market Outperform by Citizens Ahead of ASCO Presentation
$160.00
(was $133.97)
Macquarie
Celcuity price target raised to $185 from $165 at H.C. Wainwright
$185.00
(was $137.68)
Swayampakula Ramakanth
·
H.C. Wainwright
Celcuity price target raised to $183 from $150 at Wells Fargo
$183.00
(was $134.72)
Wells Fargo
Celcuity price target raised to $189 from $141 at Craig-Hallum
$189.00
(was $146.24)
Chase Knickerbocker
·
Craig-Hallum
Celcuity price target raised to $165 from $135 at Guggenheim
$165.00
(was $125.65)
Brad Canino
·
Guggenheim
Celcuity price target raised to $157 from $122 at Needham
$157.00
(was $125.65)
Needham
Celcuity price target raised to $150 from $125 at Stifel
$150.00
(was $125.65)
Stephen Willey
·
Stifel Nicolaus
Celcuity upgraded to Buy from Neutral at H.C. Wainwright
$165.00
(was $125.65)
H.C. Wainwright
Celcuity price target raised to $141 from $108 at Craig-Hallum
$141.00
(was $114.81)
Craig-Hallum
Wolfe Research Reiterates Outperform Rating on Celcuity Inc (CELC): "Relay's update does not appear to change the efficacy benchmark"
$110.00
(was $110.73)
Kalpit Patel
·
Wolfe Research
Celcuity Inc (CELC) PT Raised to $122 at Needham
$122.00
(was $115.94)
Gil Blum
·
Needham
Celcuity initiated with an Overweight at Wells Fargo
$126.00
(was $100.70)
Wells Fargo
Celcuity price target raised to $77 from $66 at H.C. Wainwright
$77.00
(was $65.22)
Swayampakula Ramakanth
·
H.C. Wainwright
Celcuity price target raised to $95 from $70 at Needham
$95.00
(was $72.14)
Needham
Celcuity Inc (CELC) PT Lowered to $39 at Stifel
$39.00
(was $16.57)
Bradley Canino
·
Stifel Nicolaus
Stifel Reiterates Buy Rating on Celcuity Inc (CELC)
$40.00
(was $15.28)
Bradley Canino
·
Stifel Nicolaus